Several studies have shown that PERK signaling is associated with multi-drug resistance in breast cancer34 and with imatinib (BCR-ABL inhibitor) resistance in chronic myeloid leukemia (CML)35. The gene discussed is EIF2AK3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.